J.P. Morgan Maintains a Buy on Novo Nordisk (NVO)

Group 1 - Novo Nordisk A/S is considered one of the best long-term low volatility stocks to buy, with a Buy rating maintained by J.P. Morgan analyst Richard Vosser and a price target set at DKK500 [1] - The company announced a definitive asset purchase and license agreement with Omeros Corporation for the candidate drug zaltenibart, which is in clinical development for rare blood and kidney disorders [2] - The agreement grants Novo Nordisk exclusive global rights for the development and commercialization of zaltenibart, with Omeros eligible for upfront and near-term milestone payments totaling $340 million, and potential total payments of up to $2.1 billion, plus tiered royalties on net sales [3] Group 2 - Novo Nordisk A/S is a global healthcare company specializing in diabetes care, with operations divided into biopharmaceuticals and diabetes and obesity care segments [4]